Insulet adds former IDEXX CEO Mazelsky to its board, shares trade higher on Nasdaq
Published on 06/26/2026 at 12:13 | Editorial responsibility: Rafael MĂĽller, Editor-in-Chief AD HOC NEWS
By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-26, 12:13.
Insulet (US45784P1012) is bringing a new heavyweight to its boardroom. According to a Business Wire distribution of the company’s release, the diabetes technology group listed on Nasdaq has appointed former IDEXX Laboratories chief executive Jonathan J. (Jay) Mazelsky as an independent director, effective 1 July 2026. Insulet board appointment release
What Insulet announced on governance
The 25 June 2026 announcement states that Mazelsky will join the Insulet board of directors as an independent member from 1 July 2026, expanding the company’s leadership bench in the medical technology space. Business Wire via Morningstar Insulet underlines that it is a global leader in tubeless insulin pump technology through its Omnipod brand. Business Wire via Morningstar
Mazelsky most recently served as president and chief executive officer of IDEXX Laboratories, a major U.S. diagnostics group, bringing additional healthcare and diagnostics expertise into Insulet’s governance structure. Business Wire via Morningstar The appointment comes as competition in diabetes devices remains intense, with peers such as Dexcom and Medtronic active in glucose monitoring and insulin delivery.
How the Insulet shares have been trading
On 25 June 2026, Insulet shares closed at 153.82 US dollars on Nasdaq, up 3.32 percent on the day, according to MarketBeat data. MarketBeat Insulet quote In after-hours trading, the shares were indicated at 152.96 dollars, a decline of 0.56 percent from the regular close. MarketBeat Insulet quote
The stock’s recent move builds on the reaction to first-quarter 2026 results, where Insulet delivered earnings above expectations and attracted fresh analyst interest. Intellectia summary of Q1 results Deutsche Bank has initiated coverage of Insulet with a Buy rating and a price target of 190 US dollars, signaling a constructive stance from a major European research house on the Nasdaq-listed name. Intellectia citing Deutsche Bank
All news and analysis on the Insulet shares
Charts, past reports and further governance updates on Insulet can be found in the dedicated topic area and on the company’s Investor Relations pages.
The product behind the Insulet stock
Insulet generates the bulk of its revenue with the Omnipod family of tubeless insulin pumps, including the current Omnipod 5 automated insulin delivery system for people with type 1 diabetes. The patch pumps are worn directly on the body and communicate wirelessly with a handheld controller.
Where the Insulet shares trade today
The Insulet shares (US45784P1012) last closed on 2026-06-25 at 153.82 US dollars on Nasdaq, based on MarketBeat pricing data.
Key data on the Insulet shares
- Company: Insulet Corporation
- ISIN: US45784P1012
- WKN: A0MRG7
- Ticker: PODD
- Trading venue: NASDAQ
- Price (as of 2026-06-25, 16:00): 153.82 USD
- Market cap: 10.1 billion USD (as of 2026-06-25)
- Sector / industry: Health Care / Medical Devices
- Index membership: S&P 500
- Next earnings date: 2026-08-06
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
